Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2014-03-17 Annual Report
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2013
2014-03-17 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 17, 2014, reporting the issuance of a press release announcing financial results for the fourth quarter and year ended December 31, 2013. The text states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of financial results. The document length is 2994 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (press release of financial results) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous filings and announcements that do not fit other categories.
2014-03-17 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Galena Biopharma, Inc. to the SEC regarding comments on their previously filed Form 10-K for the fiscal year ended December 31, 2012, and Form 10-Q for the quarter ended September 30, 2013. The letter addresses specific comments about clinical trial data and disclosure language, and proposes draft language for inclusion in future filings. It references the 10-K and 10-Q filings but does not itself contain the full annual report or quarterly report with substantive financial data. The document is a correspondence letter responding to SEC comments rather than the actual financial report. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for such correspondence and regulatory communications that do not fit other categories.
2014-03-13 English
Regulatory Filings 2014
Regulatory Filings
2014-03-11 English
PRIMARY DOCUMENT
Director's Dealing
2014-02-14 English
PRIMARY DOCUMENT
Director's Dealing
2014-02-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.